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Objective: To evaluate the safety and efﬁcacy of oral N-acetylcysteine (NAC) on digital micro-
circulation blood ﬂow in patients with Raynaud’s phenomenon (RP) secondary to systemic
sclerosis (SSc).
Methods: This was a randomized, double-blind, placebo-controlled trial in which 42 patients
with SSc received oral NAC at a dose of 600 mg tid (21 patients, mean age 45.6 ± 9.5 years)
or  placebo (21 patients, mean age 45.0 ± 12.7 years) for four weeks. The primary endpoint
was the change in cutaneous microcirculation blood ﬂow before and after cold stimulation
measured by laser Doppler imaging (LDI) at weeks 0 and 4. The frequency and severity of RP
and the number of digital ulcers were also measured at weeks 0 and 4. The adverse events
were recorded in the fourth week.
Results: There was no signiﬁcant change in digital blood ﬂow assessed by LDI before or
after cold stimulus after four weeks of NAC or placebo. Both groups showed signiﬁcant
improvement in the frequency and severity of RP attacks, with no difference between the
two  groups. At the end of the study, the placebo group had three digital ulcers, while the NAC
group showed no ulcers. NAC was well tolerated and no patient discontinued the treatment.
Conclusions: NAC orally at a dose of 1800 mg/day showed no vasodilator effect on hands’microcirculation after four weeks of treatment in patients with RP secondary to SSc.
© 2014 Elsevier Editora Ltda. All rights reserved.DOI of original article: http://dx.doi.org/10.1016/j.rbr.2014.07.001.
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N-acetilcisteína  oral  no  tratamento  do  fenômeno  de  Raynaud  secundário
à  esclerose  sistêmica:  Ensaio  clínico  randomizado,  placebo-controlado  e
duplo-cego
Palavras-chave:
Esclerose sistêmica
Fenômeno de Raynaud
Estresse oxidativo
N-acetilcisteína
Tratamento
r  e  s  u  m  o
Objetivo: Avaliar a seguranc¸a e a eﬁcácia da N-acetilcisteína (NAC) por via oral sobre o
ﬂuxo  sanguíneo da microcirculac¸ão digital em pacientes com fenômeno de Raynaud (FRy)
secundário à esclerose sistêmica (ES).
Métodos: Este foi um estudo randomizado, duplo-cego e placebo-controlado, no qual 42
pacientes com ES receberam NAC oral na dose de 600 mg, três vezes ao dia (21 pacientes,
idade média 45,6 ± 9,5 anos) ou placebo (21 pacientes, idade média 45,0 ± 12,7 anos) durante
quatro semanas. O desfecho primário do estudo foi: melhora no ﬂuxo sanguíneo da
microcirculac¸ão  cutânea antes e após estímulo frio avaliado pelo laser Doppler imaging (LDI)
nas semanas 0 e 4. A frequência e a gravidade do FRy e o número de úlceras digitais tam-
bém  foram avaliados nas semanas 0 e 4. Os efeitos adversos foram registrados na quarta
semana.
Resultados: Não houve mudanc¸a signiﬁcativa no ﬂuxo sanguíneo digital avaliado pelo LDI
antes ou depois do estímulo frio após quatro semanas de NAC ou placebo. Ambos os gru-
pos apresentaram melhora signiﬁcativa na frequência e gravidade dos ataques de FRy, sem
diferenc¸a  entre os dois. O grupo placebo apresentou três úlceras digitais enquanto o grupo
NAC  não apresentou úlceras ao ﬁnal do estudo. NAC foi bem tolerada e nenhum paciente
descontinuou o tratamento.
Conclusões: NAC por via oral na dose de 1.800 mg/dia não demonstrou efeito vasodilatador
sobre a microcirculac¸ão das mãos após quatro semanas de tratamento em pacientes com
FRy  secundário à ES.
© 2014 Elsevier Editora Ltda. Todos os direitos reservados.
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ystemic sclerosis (SSc) is a systemic autoimmune dis-
ase characterized by microvascular damage and ﬁbrosis of
kin and internal organs. Raynaud’s phenomenon (RP) is
ne of the most common and earliest manifestations of
Sc. It is characterized clinically by reversible episodes of
asospasm, usually limited to the hands and/or feet, and trig-
ered by exposure to cold or emotional stress. In patients
ith RP secondary to SSc, not only functional abnormalities
ut also structural changes are present in the microcir-
ulation, making the vasospastic events more  severe and
ossibly leading to complications such as ulceration or tissue
ecrosis.1
The pharmacological treatment of the peripheral vascular
isease secondary to SSc includes the use of vasodilators such
s calcium channel blockers, nitrates and prostanoids, and
asoconstriction inhibitors such as endothelin receptor antag-
nists and -adrenergic blockers. These agents reduce the
requency and severity of RP in patients with SSc.2–5 However,
hey are not always completely effective and new therapeutic
ptions are desirable.
Oxidative stress mediated by an increased activity of free
adicals has been implicated in the pathogenesis and progres-
6,7ion of SSc. Repeated episodes of ischemia and reperfusion
bserved in these patients cause activation of endothelial
ells, an imbalance in the relation between vasoconstric-
or and vasodilator substances and an increase in reactiveoxygen species and other toxic products. This cascade of
events contributes signiﬁcantly to the vascular damage asso-
ciated with the disease and can also activate ﬁbroblasts and
immune cells.6,8
N-Acetylcysteine (NAC) is a thiol-containing compound
(containing sulfhydryl) with a powerful antioxidant action.
As a source of sulfhydryl groups in cells, NAC directly ﬁghts
against free radicals through its interaction with the hydroxyl
radical and hydrogen peroxide.9 NAC also acts indirectly by
inducing the synthesis of glutathione, whose main function is
the removal of free radicals and the defense against oxidative
stress.9–11 Due to these properties, NAC has been used not only
as a mucolytic agent in a variety of respiratory diseases, but
also in other conditions characterized by a reduced level of glu-
tathione and by oxidative stress. NAC was shown to improve
the microcirculation blood ﬂow in smokers and promote
coronary vasodilation, besides increasing the endothelium-
dependent peripheral dilation in patients undergoing cardiac
catheterization and improving the endothelial function in
dialysis patients.10,12–14
In patients with SSc, some open studies on high-dose
intravenous (IV) NAC showed a signiﬁcant improvement in
blood perfusion and reduction in the frequency and sever-
ity of RP and in the number of active digital ulcers after
its administration.15–17 However, the IV route in continuous
infusion and the high cost of this treatment considerably
restrict its use. Only one clinical trial evaluated oral NAC in
patients with SSc, but the vascular involvement has not been
evaluated.18
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The present study aimed to evaluate the safety and efﬁcacy
of oral N-acetylcysteine on digital cutaneous microcirculation
blood ﬂow monitoring by laser Doppler imaging, and on clin-
ical symptoms of RP in patients presenting RP secondary to
SSc.
Materials  and  methods
Patients
Forty-two patients diagnosed according to the American Col-
lege of Rheumatology classiﬁcation criteria for SSc (1980),19
or the LeRoy and Medger criteria for early SSc (2001) were
selected.20 Our patients were consecutively recruited from
the Systemic Sclerosis Outpatient Clinic, Hospital São Paulo
(UNIFESP). Inclusion criteria were age ≥18 years, at least six
RP attacks per week, nail fold capillaroscopy with SD (scle-
roderma) pattern, disease duration ≤4 years from the ﬁrst
typical sign and symptom of SSc, excluding RP. Exclusion
criteria were presence of active digital ulceration, current
smoking, occupational exposure to cold environments and
vibrating agents, uncontrolled hypertension or diabetes mel-
litus, and clinical evidence of proximal peripheral arterial
disease. Three days before their inclusion in the study,
patients discontinued oral vasodilators. Other medications
remained unchanged throughout the study. All subjects
completed a written informed consent obtained in accor-
dance with the Declaration of Helsinki. The study was
approved by the Ethics Committee of UNIFESP, and was reg-
istered in the Australian New Zealand Clinical Trials Registry
(ACTRN12610000114044).
Study  design
This was a randomized, double-blind, placebo-controlled
study conducted in 2009. To minimize the temperature varia-
tion, the inclusion of patients was interrupted during summer
(January–March and December). Patients were randomized to
receive 600 mg  N-acetylcysteine or placebo in an identical cap-
sule three times a day for four weeks. Randomization and
blinding were performed by a staff member who was not par-
ticipating in the study. Patients were evaluated at three time
points: one screening visit (one or two weeks before random-
ization), at week 0 (randomization) and after four weeks of
treatment.
Outcomes
The primary outcome was the change in digital cutaneous
microcirculation blood ﬂow using laser Doppler imaging (LDI)
at time points 0 and after four weeks of NAC or placebo use.
Secondary outcomes were the number of digital ulcers in the
ﬁnal evaluation and changes in the frequency and severity of
RP attacks at 0 time point compared to week 4. Adverse events
were recorded in the fourth week. 0 1 4;5 4(6):452–458
Evaluation  of  digital  cutaneous  microcirculation  blood  ﬂow
by laser  Doppler  imaging  before  and  after  cold  stimulus
After acclimatization for 60 min  in a laboratory under con-
stant temperature of 24 ± 1 ◦C, the blood ﬂow of the dorsum of
the distal phalanx of the four ﬁngers of the left hand (exclud-
ing the thumb) was evaluated with the use of a laser Doppler
imaging unit (Moor LDI-VR, Moor Instruments, Axminster, UK)
before and after cold stimulus (CS) exposure. All subjects were
seated with the left arm placed on a ﬂat surface at heart level.
This device uses a low-power (2.0 mW)  helium–neon red laser
emission system operating at a wavelength of 633 nm with
approximately 1 mm of penetration into the skin surface. The
laser beam is directed to a selected area of skin by means of
a mirror system located at a distance of 40 cm from the skin
surface at an angle of 45◦. All images were taken with a res-
olution of 256 × 256 pixels and speed of 4 pixels/millisecond
with an acquisition time of 3 min  and 15 s for each image
(area of 10.4 cm × 16.2 cm). The blood ﬂow of the dorsum of
the four ﬁngers was determined by establishing four regions
of interest (ROI) on each ﬁnger, deﬁned as an area encompass-
ing the proximal interphalangeal joint and including the nail
bed. The blood ﬂow in the selected area was determined with
the aid of the software MoorLDI V5.2 and expressed in arbi-
trary perfusion units (PU) in relation to an internal calibration
standard device which is directly proportional to the product
of the mean velocity by the concentration of blood cells. Mean
ﬁngertip blood ﬂow (FBF) of four digits was considered for anal-
ysis. After measuring baseline FBF, patients underwent a cold
stimulus (CS) (submersion of both hands in water at 15 ◦C for
1 min) (UNITEMP 116, Fanem, Brazil). Then, after CS the FBF
was monitored for 30 min, including the time points: 1 min
(T1), 4 min  and 15 s (T4) 10 min  and 45 s (T10), 17 min  and 15 s
(T17), 20 min  and 30 s (T20) and 27 min  (T27) after CS.
Clinical  evaluation
The frequency and severity of RP attacks were recorded daily
on a standard log book completed by the patient during the
week previous to week 0 and during week 4. Patients were
instructed to immediately record the event and the attack
severity (in a scale with 0–10 range) whenever an RP attack
occurred. The number of digital ulcers was recorded at base-
line (week 0) and at the end of week 4. Adverse events were
also recorded in week 4.
Statistical  analysis
All results were expressed as mean ± standard deviation (SD).
For comparison between placebo and NAC groups, the paired
Student t test, Mann–Whitney test or chi-squared test were
used. To compare the values of LDI and of severity and fre-
quency of RP over time, ANOVA with repeated measures was
used. For all analyses, the signiﬁcance value <0.05 was con-
sidered. The statistical analysis was performed using SPSS
statistical software (version 15.0 for Windows, SPSS Inc.,
Chicago, IL).
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esults
emographic  data
f the 42 patients with SSc included, 21 received oral NAC
mean age 45.6 ± 9.5 years) and 21 received placebo (mean
ge 45.0 ± 12.7 years) (Table 1). Seven patients (16.6%) had an
arly form of SSc according to LeRoy and Medsger criteria,20 14
33.3%) limited cutaneous disease, and 21 (50%) diffuse cuta-
eous disease. According to Table 1, there were no differences
n demographic and clinical characteristics between NAC and
lacebo groups. Before the start of the study, 28 patients were
aking calcium channel blockers (nifedipine or amlodipine),
ight were taking ACE inhibitors, and ﬁve were taking losartan.
here was no signiﬁcant difference in age, gender, RP duration
nd disease duration among patients with diffuse cutaneous
orm, limited cutaneous form, and those with early SSc (data
ot shown).
igital  cutaneous  microcirculation  blood  ﬂow  and  clinical
utcomes
here was no signiﬁcant difference between NAC and placebo
roups in FBF values before (FBF 318.5 ± 204.5 vs. 224.5 ± 180.1
U, respectively, P = 0.122) and after (P = 0.432 for T1, P = 0.164
or T4, P = 0.269 for T10, P = 0.616 for T17, P = 0.344 for T20,
 = 0.150 for T27) cold stimulus on the baseline assessment.
here was no signiﬁcant difference in FBF values measured
efore and in each time point after CS when comparing
he values of week 0 and week 4 in NAC group (Fig. 1A).
n placebo group, there was no signiﬁcant difference in FBF
efore and in each time point after CS when weeks 0 and
 were compared (Fig. 1B). When patients with diffuse cuta-
eous, limited cutaneous and early SSc forms were evaluated
n separate groups, also there was no signiﬁcant difference in
Table 1 – Clinical and demographic characteristics of patients w
N-acetyilcystein
Age (years) 45.6 ±
Gender M/F 21/0 
Classiﬁcation 
Diffuse 9 
Limited 8 
Early 4 
Duration of RP (years) 5.5 ± 1
Disease duration (years) 2.5 ± 1
ANA 17 
Microscars, resorption or digital amputation 8 
Treatment of RP before inclusion
Calcium channel blocker 16 
ACE inhibitor 3  
Losartan 2 
Sildenaﬁl 1 
Pentoxifylline 2 
RP, Raynaud phenomenon; ANA, positive antinuclear antibodies by indire
enzyme. 4;5 4(6):452–458 455
FBF values after the treatment with NAC or placebo (data not
shown).
Both groups showed signiﬁcant improvement in the fre-
quency and severity of RP attacks after four weeks of treatment
(Table 2), with no signiﬁcant difference between the two
groups. The mean reduction in the frequency of RP attacks per
week was 5.9 in placebo group and 5.1 in NAC group (P = 0.865).
The mean reduction in severity of RP attacks was 1.7 in placebo
group and 3.0 in NAC group (P = 0.074). In the same line, there
was no signiﬁcant difference in the frequency of RP attacks
(P = 0.428) and RP severity (P = 0.716) between NAC and placebo
groups at baseline. Placebo group presented three new digital
ulcers after four weeks of treatment, while NAC group showed
no new ulcerations (Table 2).
Oral NAC was generally well tolerated, two  patients had
epigastric pain and a third exhibited an increase in menstrual
ﬂow. At the end of four weeks, no patient had discontinued the
treatment. There were no adverse events in placebo group.
Discussion
This was the ﬁrst double-blind placebo-controlled study to
evaluate the efﬁcacy of oral N-acetylcysteine for the treat-
ment of RP secondary to SSc. Laser Doppler imaging, a method
that allows an objective measure of the microvascular blood
ﬂow, was used to assess the response to treatment.12 After
four weeks, there was no signiﬁcant change in ﬁngertips blood
ﬂow before or after cold stimulus, both in NAC group and in
placebo group. Interestingly, both groups showed signiﬁcant
improvement in RP attacks’ frequency and in severity of RP,
conﬁrming the contribution of the placebo effect in clinical
22,23trials on patients with RP. NAC was safe and well tolerated
by almost all patients.
Several alternatives are suggested for the treatment of
RP secondary to SSc.4,5,23,24 Conventional vasodilator drugs
ith SSc.
e Group (n = 21) Placebo Group (n = 21) P
 9.5 45.0 ± 12.7 0.863
20/1 1.000
0.350
12
6
3
.9 4.9 ± 1.6 0.275
.2 2.8 ± 1.3 0.442
14 0.392
6 0.578
12 –
5 –
3 –
0 –
2 –
ct immunoﬂuorescence on HEp-2 cells; ACE, angiotensin converting
456  r e v b r a s r e u m a t o l . 2 0 1 4;5 4(6):452–458
2720171041
0
50
100
150
200
250
300
350
400
D
ig
ita
l b
lo
od
 fl
ow
 (P
U)
Baseline
Time (min) Time (min)
Week 0   Week 4 Week 0   Week 4
2720171041Baseline
0
50
100
150
200
250
300
350
P=0.614
P=0.756
P=0.792
P=0.498
P=0.876
P=0.986 P=0.131
P=0.313
P=0.192
P=0.715
P=0.616
P=0.314
P=0.339A  B
D
ig
ita
l b
lo
od
 fl
ow
 (P
U) P=0.170
Fig. 1 – Mean ﬁngertips blood ﬂow in four phalanges (FBF) measured at baseline (week 0) and after four weeks of treatment
with N-acetylcysteine (A) or placebo (B) before and at different time points after cold stimulus. P values correspond to a
comparison between week 0 and week 4.
such as calcium channel blockers, -adrenergic inhibitors,
angiotensin converting enzyme (ACE) inhibitors, angiotensin
receptor blockers, phosphodiesterase inhibitors, and nitrates
(usually topical) are currently used for the treatment of Ray-
naud’s phenomenon with heterogeneous results.23–25 More
recently, prostaglandin analogs and endothelin receptor
antagonists (bosentan) showed promising results in the treat-
ment and prevention of ischemic ulcers in SSc.2,26 However,
the IV route and the more  expensive costs limit the prescrip-
tion of these drugs for those patients with more  severe disease.
Despite considerable evidence that oxidative stress is
involved in the pathogenesis of SSc, few studies have eval-
uated the effects of oral antioxidants in the treatment of RP
secondary to SSc. Probucol, a powerful antioxidant, has led
to a reduction in the frequency and severity of RP attacks in
a study of 40 patients with primary and secondary RP.27 In
contrast, another study showed no beneﬁt after 10 weeks of
treatment with a combination of antioxidants, micronutrients
and allopurinol, or after three weeks of vitamin E, in patients
with SSc.28
In conditions characterized by oxidative stress such as
smoking and heart disease and in clinical situations in which
glutathione levels are decreased, NAC appears to be effective
as a complementary therapy.9 In addition to its antioxidant
properties, oral NAC also appears to have vasodilator action
on the microvasculature, which could result in a beneﬁcial
effect on vascular changes and on episodes of vasospasm in
patients with SSc. On the other hand, when added to standard
therapy, NAC was able to preserve the vital capacity and DLco
in patients with idiopathic pulmonary ﬁbrosis.29
Table 2 – Number and severity of Raynaud’s phenomenon attac
weeks of treatment with N-acetylcysteine or placebo.
Placebo Group 
Week 0 Week 4 
Number of RP attacks/week 15.9 ± 12.7 10 ± 8.4 (−37%) 
RP severity 8.5 ± 2.0 6.8 ± 2.1 (−20%) 
Number of digital ulcers 0 3 In SSc patients, high-dose intravenous NAC has been sug-
gested as a valuable and effective treatment for RP. The efﬁcacy
and tolerability of a ﬁve-day continuous infusion of NAC
in high doses was evaluated in an open label study of 22
patients with SSc.15 There was a signiﬁcant decrease in the
frequency and severity of RP attacks and in the number of
active ulcers after treatment. An improved digital perfusion,
evaluated by plethysmography after treatment, also occurred
in most patients.
More recently, two other studies have evaluated the efﬁ-
cacy of long-term treatment with IV NAC in patients with SSc,
with positive results.16,17 In our hospital, we also conducted
a pilot study with high-dose IV NAC in three patients with
SSc and active ischemic ulcers of the extremities.30 Over the
course of two months, all patients showed a decrease in diam-
eter of at least one ulcer, and two of them showed complete
healing of an ulcer. The present study evaluated the efﬁcacy
of oral NAC, instead of IV NAC. It is known that the intact NAC
molecule has a low oral bioavailability. Following an oral dose,
the majority of the NAC molecule is metabolized to other com-
pounds, such as cysteine and inorganic sulﬁte, and the greater
part of its activity and protective effects is credited to these
metabolites.9,31 However, we  cannot exclude that the lower
bioavailability of oral NAC might have inﬂuenced our results.
Our study has some limitations, such as its short duration
and small sample size. The dose of NAC used may also have
contributed to the observed lack of improvement in digital
blood ﬂow. The dose of 1.8 g per day was the same used in
a clinical trial of oral NAC for the treatment of idiopathic pul-
monary ﬁbrosis.29 The usual dosage of NAC as a mucolytic and
ks and number of digital ulcers before and after four
N-acetyilcysteine Group
P Week 0 Week 4 P
<0.000 12.3 ± 13.8 7.2 ± 4.5 (−41%) <0.000
<0.001 8.7 ± 1.1 5.7 ± 2.6 (−35%) <0.000
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ntioxidant agent in chronic obstructive pulmonary disease is
uch lower (generally 600 mg  per day). However, in other cir-
umstances, such as acetaminophen toxicity, the NAC dosage
s much higher.32
Our study was conducted before the publication of the new
CR/EULAR 2013 classiﬁcation criteria for SSc.33 We  chose to
nclude patients with a diagnosis of early SSc according to
eRoy and Medsger criteria, aiming to include patients with
ecent disease in whom a possible effect of NAC might be more
mportant. Of the seven patients with early SSc, only three
ould meet the new ACR/EULAR 2013 criteria.
An important ﬁnding of this study was the improvement of
linical outcomes (number of attacks and RP severity) in both
roups after treatment with NAC or placebo. This fact conﬁrms
he contribution of placebo effect in patients who are partic-
pants of clinical trials, which has been shown in previous
tudies in patients with RP.3,34–36 In this context, our results
einforce the need to use more  sensitive objective methods,
uch as LDI, for the evaluation of RP and of microcirculatory
lood ﬂow in therapeutic trials. In a previous study conducted
y our group, the LDI technique proved to be a sensitive and
bjective method for the evaluation of digital blood ﬂow in
atients with RP secondary to SSc.21 LDI has the advantage
f being a noninvasive method that allows the measurement
f blood perfusion over a wide area of skin surface, thereby
roviding more  reproducible results.21,37
The development of new digital ulcers is an important out-
ome in clinical trials on RP secondary to SSc. In the present
tudy, three patients in placebo group developed new digi-
al ulcers, while new ulcers were not observed in NAC group.
espite this favorable observation, the short duration of the
tudy and the small number of observed ulcers do not allow
eﬁnitive conclusions about the ability of NAC to prevent the
evelopment of ulcers. Multicentric studies with a long-term
ollow-up are needed to better assess this issue.
In summary, the oral NAC dose of 1800 mg/day did not lead
o a signiﬁcant improvement in digital cutaneous microcircu-
ation blood ﬂow in this short-term study in patients with RP
econdary to SSc. Additional studies with a longer duration
f treatment and higher doses of NAC are needed to assess
hether oral NAC may promote some beneﬁt as an antioxi-
ant therapy in the vascular involvement of SSc.
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